Neurocrine Biosciences Total Liabilities 2010-2025 | NBIX

Neurocrine Biosciences total liabilities for the quarter ending March 31, 2025 were $1.152B, a 6.05% increase year-over-year.

  • Neurocrine Biosciences total liabilities for 2024 were $1.129B, a 10.75% increase from 2023.
  • Neurocrine Biosciences total liabilities for 2023 were $1.019B, a 54.24% increase from 2022.
  • Neurocrine Biosciences total liabilities for 2022 were $0.661B, a 5.38% decline from 2021.

Neurocrine Biosciences Total Liabilities 2010-2025 | NBIX

  • Neurocrine Biosciences total liabilities for 2024 were $1.129B, a 10.75% increase from 2023.
  • Neurocrine Biosciences total liabilities for 2023 were $1.019B, a 54.24% increase from 2022.
  • Neurocrine Biosciences total liabilities for 2022 were $0.661B, a 5.38% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$95B
Zoetis (ZTS)$66.3B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$41.7B
Summit Therapeutics (SMMT)$18.2B
Sandoz Group AG (SDZNY)$17.7B
Merck (MKKGY)$17.2B
Astellas Pharma (ALPMY)$16.9B
Shionogi (SGIOY)$14.1B
United Therapeutics (UTHR)$12.8B
IPSEN (IPSEY)$8.6B
Orion OYJ (ORINY)$8B
Madrigal Pharmaceuticals (MDGL)$6.7B
Stevanato Group S.p.A (STVN)$6.6B
Corcept Therapeutics (CORT)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.8B
Ono Pharmaceutical (OPHLF)$5.5B
Grifols, S.A (GRFS)$4.9B
Ionis Pharmaceuticals (IONS)$4.5B
Soleno Therapeutics (SLNO)$3.2B
Crinetics Pharmaceuticals (CRNX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2.2B
Hypermarcas (HYPMY)$2.1B
NewAmsterdam Pharma (NAMS)$1.8B
Centessa Pharmaceuticals (CNTA)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B